Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy

被引:160
作者
Dore, GJ
McDonald, A
Li, YM
Kaldor, JM
Brew, BJ
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, HIV Immunol Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Dept Neurol, Sydney, NSW 2010, Australia
关键词
HIV; AIDS dementia complex; antiretroviral therapy;
D O I
10.1097/00002030-200307040-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the effect of introduction of highly active antiretroviral therapy (HAART) on survival following AIDS dementia complex (ADC). Methods: Australian AIDS notification data in the period 1993-2000 were examined. In order to examine the impact of HAART, two periods of AIDS diagnoses were chosen: pre-HAART (1993-1995) and HAART (1996-2000). Median survival was based on Kaplan-Meier estimates, with examination of factors influencing survival in a Cox proportional hazards model. Results: In the period 1993-2000 in Australia, 5017 initial AIDS illnesses were diagnosed among 4351 AIDS patients. The proportion of AIDS cases with ADC increased from 5.2% in 1993-1995 to 6.8% in 1996-2000 (P=0.029). Median survival following AIDS increased from 19.6 months for those diagnosed with AIDS in 1993-1995 to 39.6 months for those diagnosed in 1996-2000 (P < 0.0005). Median survival following ADC increased to a greater extent than that for all other AIDS illnesses, from 11.9 months in 1993-1995 to 48.2 in 1996-2000 (P < 0.0005). Most striking was the increase in survival among those with ADC and a CD4 cell count < 100 x 10(6) cells/l at diagnosis; 5.1 months in 1993-1995 to 38.5 months in 1996-2000 (P < 0.0005). Conclusion: Although there has been a proportional increase in ADC at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1539 / 1545
页数:7
相关论文
共 44 条
  • [1] Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era
    Abgrall, S
    Rabaud, C
    Costagliola, D
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) : 1747 - 1755
  • [2] [Anonymous], 1999, MMWR Recomm Rep, V48, P1
  • [3] [Anonymous], 1996, Lancet, V348, P283
  • [4] [Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
  • [5] *AUSTR NAT COUNC A, 1994, ANCA B, V18, P1
  • [6] Variable progression of HIV-associated dementia
    Bouwman, FH
    Skolasky, RL
    Hes, D
    Selnes, OA
    Glass, JD
    Nance-Sproson, TE
    Royal, W
    Dal Pan, GJ
    McArthur, JC
    [J]. NEUROLOGY, 1998, 50 (06) : 1814 - 1820
  • [7] Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
    Brodt, HR
    Kamps, BS
    Gute, P
    Knupp, B
    Staszewski, S
    Helm, EB
    [J]. AIDS, 1997, 11 (14) : 1731 - 1738
  • [8] *CDCP, 1987, MMWR-MORBID MORTAL W, V36, pS3
  • [9] Impact of opportunistic disease on survival in patients with HIV infection
    Chaisson, RE
    Gallant, JE
    Keruly, JC
    Moore, RD
    [J]. AIDS, 1998, 12 (01) : 29 - 33
  • [10] Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses
    Conti, S
    Masocco, M
    Pezzotti, P
    Toccaceli, V
    Vichi, M
    Boros, S
    Urciuoli, R
    Valdarchi, C
    Rezza, G
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (05) : 451 - 458